Brief: Coeptis Therapeutics To Pursue Phase 2 Program For Allogeneic NK Cell Therapy
07/02/2024 12:45
Feb 7 (Reuters) - Coeptis Therapeutics Holdings Inc
COEP.O :
* COEPTIS THERAPEUTICS TO PURSUE PHASE 2 PROGRAM USING
PROPRIETARY
FIRST-IN-CLASS ALLOGENEIC NK CELL THERAPY FOR THE TREATMENT OF
VIRAL INFECTIONS
Source text for Eikon: ID:nPn8fF60fa
Further company coverage: COEP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Z Squared (Delaware)
See all newsBrief: Z Squared Inc. Signs Definitive Agreement To Acquire 100% Of Paradox Data And Its Union County Campus
Brief: Z Squared, Inc. To Acquire Majority Interest In Paradox Data And Its Union County Campus, A Next-Generation Data Center Development Targeting Up To 150 MW Of Firm Power
Brief: Z Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement To Support Ai Infrastructure Buildout
Brief: Z Squared Appoints Jon Najarian, Pete Najarian, Marc Lopresti And Jay Zapata To Newly Formed Advisory Board
Brief: Z Squared Announces Executive Leadership Appointments To Advance Ai Infrastructure Strategy